Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

(3) Cardio-Pulmo-Renal Rehabilitation > S1 L3.2: Chronic Lung Diseases > Flashcards

S1 L3.2: Chronic Lung Diseases Flashcards

1
Q

A chronic inflammatory disorder of the airway mucosa associated with airway hyperresponsiveness

“Big form of allergy”

A

Bronchial Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sx of Bronchial Asthma

A

○ Recurrent episodes of wheezing
○ Breathlessness d/t narrowed airway
○ Chest tightness
○ Mucus production d/t inflammation
○ Coughing d/t irritation of the airways eliciting asthmatic s/sxs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk Factors for Asthma

Influence susceptibility to development of asthma in predisposed individuals, precipitate asthma exacerbations, and/or cause symptoms to persist

A

Environmental Factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk Factors of Asthma

Predisposed individuals to, or protect them from, developing asthma; could be genetic

A

Host Factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Inflammation makes the airway hyperresponsive → [?]

A

Develop sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Statement 1: Allergens, sensitizers, viruses, or air pollutants come in contact with our airways
Statement 2: Our immune system (+ eosinophils, inflammatory cells) is poised to react to these triggers, their interaction results to inflammation

a. TF
b. FT
c. TT
d. FF

A

c. TT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

With triggers, the normal airway’s muscular portion contracts (bronchoconstriction) → [?] → result to [?]

A

With triggers, the normal airway’s muscular portion contracts (bronchoconstriction) → will narrow down airways → result to limited airflow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Statement 1: Asthmatic people, whenever they have attacks, become dyspneic or hypoxemic d/t bronchodilation
Statement 2: Wheezes are low-pitched sounds caused by narrowed airways

a. TF
b. FT
c. TT
d. FF

A

d. FF

1. Bronchoconstriction; 2: High-pitched

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Acute Signs and Sx of Asthma

A
  1. Dyspnea
  2. Wheezing (especially upon expiration)
  3. Flaring of Nostrils
  4. Interrupted Talking
  5. Agitation
  6. Chronic/recurrent cough
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Heart is not functioning well (not pumping well), therefore blood fluid that should move forward goes back and returns to the lungs.

A

Cardiac Wheeze

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Severity of Asthma Attack

Alert: Agitated
Breathlessness: Even at rest
Talks in: Words
Wheeze: Loud
Accessory Muscle: Used
RR: Often >30
PR: >120
PaO2: <60, possible cyanosis
PCO2: >45

A

Severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Severity of Asthma Attack

Alert: May show agitation
Breathlessness: On walking
Talks in: Sentences
Wheeze: Moderate
Accessory Muscle: Usually not Used
RR: Inc
PR: 100
PaO2: Normal
PCO2: <45

A

Mild

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Severity of Asthma Attack

Alert: Confused
Breathlessness: -
Talks in: -
Wheeze: Absent
Accessory Muscle: -
RR: -
PR: <60 (bradycardia)
PaO2: -
PCO2: -

A

Pending Arrest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Severity of Asthma Attack

Alert: Agitated
Breathlessness: On walking
Talks in: Phrases
Wheeze: Loud
Accessory Muscle: Used
RR: Inc
PR: 100-120
PaO2: >60
PCO2: <45

A

Moderate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic Asthma Severity while on Treatment

Daytime Symptoms: Monthly
Nocturnal Awakenings: Less than monthly
Rescue Beta 2 Use: Less than weekly
PEF/FEV1: >80% of predicted
Tx needed: Occasional prn Beta 2 only

A

Intermittent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Chronic Asthma Severity while on Treatment

Daytime Symptoms: Weekly
Nocturnal Awakenings: Monthly-Weekly
Rescue Beta 2 Use: Weekly-Daily
PEF/FEV1: 60-80% of predicted
Tx needed: Reg ICS + LABA combination

A

Persistent Mild/Moderate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Chronic Asthma Severity while on Treatment

Daytime Symptoms: Daily
Nocturnal Awakenings: Nightly
Rescue Beta 2 Use: Several times/day
PEF/FEV1: <60% of predicted
Tx needed: Combination of ICS + LABA + OCS

A

Persistent Severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Medications

Used regularly to control chronic symptoms and prevent asthma attacks

A

Long-term-control medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Medications

Used as needed for rapid, short-term relief of symptoms during an asthma attack

A

Quick relief medications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Medications

Decrease sensitivity to allergens

A

Allergy Control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Modified T/F
Facts about COPD

A. In 2010, the WHO estimated 2.74 million deaths worldwide from COPD
B. COPD is the 2nd leading cause of death in the US

A

FF

A. WHO estimated this in 2000
B. 4th leading cause of death in the US

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the primary cause of COPD?

A

Cigarette smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

T/F

Vape is safer in terms of cardiac & lung problems

A

False. Vape may be safer in terms of cardiac problems, but in the lungs it is not.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Modified T/F
Facts about COPD

A.Characterized by airflow limitation that is fully reversible
B. Usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles or gasses

A

FT

A. Characterized by airflow limitation that is not fully reversible. You can alleviate worsening only.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the 3 classifications of COPD?

A

CHRONIC BRONCHITIS
EMPHYSEMA
SMALL AIRWAYS DISEASE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Matching type

  1. Destruction and enlargement of the alveoli, Anatomically defined
  2. Cough and sputum production for at least 3 months in a row of 2 of consecutive years, Clinically defined
  3. A condition in which small bronchioles are narrowed but pathology is same

A. CHRONIC BRONCHITIS
B. EMPHYSEMA
C. SMALL AIRWAYS DISEASE

A
  1. B
  2. A
  3. C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Matching type
MANIFESTATIONS

  1. Inflamed small airways; bronchioles are destroyed
  2. Airflow narrowing is structural and permanent
  3. “Pink puffer”
  4. Alveolar destruction
  5. Blue bloaters

A. CHRONIC BRONCHITIS
B. EMPHYSEMA

A
  1. A
  2. B
  3. B
  4. B
  5. A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Matching type
RISK FACTORS OF COPD

  1. Genes
  2. Lung growth
  3. Tobacco smoke
  4. Hyperresponsiveness
  5. Education

A. HOST FACTORS
B. EXPOSURE

A
  1. A
  2. A
  3. B
  4. A
  5. B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Modified T/F
COPD PATHOGENESIS

A. You are predisposed to COPD because of your genes and you have the environment to culture it
B. Disease particles in gasses promote lung inflammation

A

TF

B. Noxious particles in gasses promote lung inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

COPD PATHOGENESIS

Depending on how the body reacts to inflammation, excessive reaction can lead to _______

A

Fibrosis

  • scars / dead tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Matching type
COPD PATHOGENESIS

  1. Loss of alveolar attachments
  2. Airway inflammation
  3. Airway remodeling
  4. Decrease of elastic recoil

A. Small airway disease
B. Parenchymal destruction

A
  1. B
  2. A
  3. A
  4. B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Modified T/F
COPD

A. Irreversible causes of airflow limitation include accumulation of inflammatory cells, mucus, and plasma exudate in bronchi
B. Reversible causes of airflow limitation include fibrosis and narrowing of the airways, loss of elastic recoil due to alveolar destruction, & destruction of alveolar support that maintains patency of small airways

A

FF

A. Accumulation of inflammatory cells, mucus, and plasma exudate in bronchi - REVERSIBLE
B. Fibrosis and narrowing of the airways, loss of elastic recoil due to alveolar destruction, & destruction of alveolar support that maintains patency of small airways - IRREVERSIBLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Matching type
COPD PATHOGENESIS

  1. Smooth muscle construction in peripheral and central airways
  2. Loss of elastic recoil due to alveolar destruction
  3. Destruction of alveolar support that maintains patency of small airways
  4. Fibrosis and narrowing of the airways

A. REVERSIBLE
B. IRREVERSIBLE

A
  1. A
  2. B
  3. B
  4. B
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

T/F

Common symptoms to aid in the diagnosis of COPD are cough, sputum, & fever.

A

FALSE.

Cough, sputum, & DYSPNEA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Modified T/F
Diagnosis of COPD

A. Symptoms (cough, sputum, dyspnea) are the only thing to look out for when doing a patient’s subjective examination.
B. Diagnosis of COPD is similar to asthma

A

FT

A. Symptoms (cough, sputum, dyspnea) and history of exposure to risk factors (tobacco, occupation, indoor & outdoor pollution)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

T/F
Diagnosis of COPD

The patient cannot be subjected to spirometry without the s/sx.

A

FALSE

The patient can be subjected to spirometry even without the s/sx.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

T/F

FEV1 is fast in COPD patients.

A

FALSE.

FEV1 is slow in COPD patients

38
Q

Matching type
COPD CLASSIFICATION BY SEVERITY

  1. With or w/o symptoms of smoker’s cough, little or no breathlessness
  2. Breathlessness on exertion
  3. Chronic cough, sputum production
  4. Breathlessness on any exertion/at rest
  5. Polycythemia in advanced disease, especially during
  6. Variable abnormal signs (general reduction in breath sounds, presence of wheezes)

A. Stage 0
B. Stage 1
C. Stage 2
D. Stage 3
E. Stage 4

A
  1. B and C
  2. D
  3. A
  4. E
  5. E
  6. C and D
39
Q

Modified T/F
Goals of therapy for COPD

a. Cure disease
b. Improve quality of life

A

FT

a. COPD is irreversible; goal is to prevent disease progression

40
Q

Matching type
COPD therapy

  1. Beta agonists
  2. Pulmonary rehabilitation
  3. Smoking cessation
  4. Vaccination
  5. Lung volume reduction surgery

A. PHARMACOTHERAPY
B. NONPHARMACOLOGIC THERAPY

41
Q

Modified T/F
COPD

PULMONARY REHAB IS AIMED AT IMPROVING QUALITY OF LIFE BY
A. Decreasing respiratory symptoms and complications
B. Increasing hospitalizations

A

TF

B. Reducing hospitalizations

42
Q

Give the 6 components of pulmo rehab programs

A

Medical management
Exercise
Breathing retraining
Education
Emotional support
Nutrition counseling

43
Q

Modified T/F

A. Asthma is related to a noxious agent
B. COPD is related to a sensitizing agent

A

FALSE

Asthma is related to a sensitizing agent
COPD is related to a noxious agent

44
Q

Modified T/F

A. Both asthma and COPD can present with wheezing
B. COPD is common in older age usually d/t smoking

45
Q

Matching type

  1. Dyspnea w/ exertion (progressive over time)
  2. Trigger: Occupational antigens
  3. Pursed lip breathing
  4. Prolonged expiration
  5. Eosinophilia in CBC

A. Asthma
B. COPD

46
Q

Matching type

  1. Reduced FEV1 & FEV1/FVC
  2. Spirometry values usually do not return to normal values even w/ treatment
  3. Early inspiratory crackles
  4. Alpha-1 antitrypsin level is normal

A. Asthma
B. COPD
C. Both

47
Q

Main pathology in chronic restrictive lung diseases

A

Reduced lung compliance (Lungs have difficulty in expanding)

48
Q

Modified T/F

A. In chronic restrictive lung diseases, less pressure needed to expand the lungs
B. In chronic restrictive lung diseases, the lungs are stiff

A

FT

A. MORE pressure is needed to expand the lungs

49
Q

Modified T/F
Chronic restrictive lung diseases - Pulmonary function test

A. ↑ TLC, FRC, RV, FEV1, FVC
B. The ratio FEV1/FVC usually normal

A

FT

A. ↓ TLC, FRC, RV, FEV1, FVC

50
Q

The basement membrane, interstitial tissue, endothelial cell, & epithelial cell are part of the ______ barrier.

A

Gas Exchange Barrier (membrane where O2 and CO2 exchange)

51
Q

Explain the mechanism of chronic restrictive lung diseases

A

Damage to epithelium and vessels → abnormal VQ → hypoxia → cyanosis

52
Q

Modified T/F
Chronic restrictive lung diseases

A. Chest wall abnormality is a primary lung disease
B. Primary lung diseases can be further categorized to acute and chronic

A

FT

A. Chest wall abnormality is NOT a primary lung disease

53
Q

Modified T/F
Chronic restrictive lung diseases

A. Chest wall abnormalities can be caused by deformities or neuromuscular diseases
B. Neuromuscular diseases that can cause chronic restrictive lung diseases are MG, ALS, MS, muscular dystrophy, myopathy

54
Q

T/F

Patients with acute respiratory distress syndrome (ARDS) live about 5 years after diagnosis.

A

FALSE.

Most die immediately

55
Q

Occupational hazards for chronic primary lung disease include:

A. Asbestosis
B. Silicosis
C. Theophylline
D. Coal worker pneumoconiosis

A

A, B, & D only

56
Q

What represents 15% of non-infectious diseases of lungs?

A

CHRONIC RESTRICTIVE LUNG DISEASES

57
Q

TRUE about chronic restrictive lung diseases?

  1. End-stage: diffuse interstitial pulmonary fibrosis (Honeycomb lung)
  2. It is a group of different diseases with similar clinical, pulmonary function test, and pathological findings
58
Q

Diffuse interstitial pulmonary fibrosis is also called

A

Honeycomb lung

59
Q

Radiation can also burn the lungs, creating ________ in the lungs

60
Q

Most common form of idiopathic interstitial lung disease, also called usual Interstitial pneumonia

A

IDIOPATHIC PULMONARY FIBROSIS

61
Q

Modified T/F
IDIOPATHIC PULMONARY FIBROSIS

A. 60% idiopathic, but 40% is associated with collagen vascular diseases
B. Affectation: Male < female

A

FF

A. 80% idiopathic, but 20% is associated with collagen vascular diseases
B. Male > female, 60 y/o

62
Q

Modified T/F
IDIOPATHIC PULMONARY FIBROSIS

A. Dx takes time. Usually undergoes numerous rule-outs before being dx c IPF
B. Idiopathic Pulmonary Fibrosis is considered to be a diagnosis during the early stages of the condition

A

FF

A. 80% idiopathic, but 20% is associated with collagen vascular diseases
B. MDs consider a lot of diseases first. If there is no other possible diagnosis, then it can be Idiopathic Pulmonary Fibrosis

63
Q

CLINICAL PRESENTATION OF THIS DISEASE IS

  • Gradual, non-productive cough
  • Progressive dyspnea, cyanosis
  • Inspiratory crackles
  • Finger clubbing
  • Poor response to therapy
  • Bad prognosis (worst)
  • Mean survival 2-4 years
A

IDIOPATHIC PULMONARY FIBROSIS

64
Q

SALIENT FEATURES OF THIS DISEASE IS

  • Bilateral hilar lymphadenopathy (kulani)
  • Lung involvement, lung nodules
  • Other organs: skin, eye, any tissue
A

SARCOIDOSIS

65
Q

T/F ABOUT SARCOIDOSIS

  1. Multisystem diseases
  2. Known etiology
  3. Affects adults younger than <50 y/o
  4. Common in asians
  5. Common in non-smokers
A
  1. T
  2. F - UNKNOWN ETIOLOGY
  3. F - Adult, younger than <40 y/o
  4. F - Common in US blacks; not common in PH
  5. T
66
Q

T/F

Sarcoidosis has better prognosis compared to IPF

67
Q

Sarcoidosis progression type

A

Progressive or relapsing remitting disease

68
Q

Sarcoidosis immunologic factors

A
  • Activated CD4 T-cells
  • Increase number of CD4 T-cells
  • High level of IL-2, Interferon-gamma, IL-8, TNF
69
Q

Sarcoidosis genetic factors

A
  • Familial, racial clustering
  • Association with HLA-A1, HLA-B8
70
Q

Sarcoidosis Environmental factors

A
  • Viral infection, mycobacteria
  • Unsure but typically associated with viral infection
71
Q
  • IMMUNE MEDIATED DISEASE
  • Inflammatory disease
  • Affect alveoli mainly (allergic alveolitis)
  • Restrictive disease
A

HYPERSENSITIVITY PNEUMONITIS

72
Q

Acute hypersensity pneumonitis presents with

A

4-6 hours following exposure to the pathogen:
Fever, cough, dyspnea

73
Q

Chronic hypersensity pneumonitis presents with

A

Cough, dyspnea, weight loss

74
Q

Matching type
HYPERSENSITIVITY PNEUMONITIS CAUSES

  1. Pigeon breeder lungs
  2. Humidifier lung
  3. Farmer lung

A. Fungal/ bacterial
B. Animal product

75
Q

Morphology of what disease:

  • Particles: not usually sEEN
  • Inflammation, edema, peribronchial
  • Fibrosis
A

HYPERSENSITIVITY PNEUMONITIS

76
Q

COLLAGEN VASCULAR DISEASE is similar to what other restrictive lung disease?

A

Idiopathic pulmonary fibrosis

77
Q

CAUSES OF COLLAGEN VASCULAR DISEASE?

A

Scleroderma
Polymyositis/ dermatomyositis
Systemic lupus erythematosus
Rheumatoid arthritis
Ankylosing spondylitis

78
Q

MODIFIED T/F

A. WEGENER GRANULOMATOSIS affect upper respiratory tract only
B. Wegener’s granulomatosis is a necrotizing vasculitis

A

FT

A. Affect both upper and lower respiratory tract

79
Q

Matching type

WEGENER GRANULOMATOSIS SYMPTOMS
1. sinusitis
2. hemoptysis
3. Nasal perforation
4. Cough

A. UPPER RESPIRATORY TRACT
B. LOWER RESPIRATORY TRACT

80
Q

Matching type

1.Nitrofurantoin
2. Amiodarone
3. Gold
4. Dilantin
5. Bleomycin

A. Anti-seizure drug
B. Used for cancer
C. Antibiotic
D. Cardiac drug that controls cardiac arrhythmia
E. Disease-modifying antirheumatic drug (DMARD)

81
Q

Work-up MD may ask for in pts with Chronic lung diseases

A

Pulmonary function test
Chest X-ray (CXR)
High resolution CT Scan
Lung Biopsy
Blood tests directed by clinical assessment
Bronchoalveolar Lavage

82
Q

When is steroids given as treatment?

A

If you don’t know the cause, but you know the pathomechanics

83
Q

Matching type

  1. Cyclophosphamide
  2. Antibiotics
  3. Steroids
  4. Oxygen supplementation

A. Anti-fibrosis/anti-inflammatory
B. If there is a superimposed infection or pneumonia
C. Very effective anti-inflammatory agent but has many side effects
D. Required due to fibrosis

84
Q

MODIFIED T/F

A. Prognosis for collagen vascular diseases, eosinophilic pneumonia, BOOP, and drug-induced lung diseases is still unfavorable even with treatment
B. Sarcoidosis has better prognosis that other restrictive lung diseases

A

FT

A. Prognosis for collagen vascular diseases, eosinophilic pneumonia, BOOP, drug-induced lung diseases is generally favorable with treatment

85
Q

What severity of COPD needs avoidance of risk factors and education?

86
Q

What severity of COPD needs smoking cessation?

87
Q

What severity of COPD needs vaccination?

88
Q

What severity of COPD needs short-acting bronchodilator PRN?

89
Q

What severity of COPD needs regular use of single or combined long-acting bronchodilators?

90
Q

What severity of COPD needs inhaled steroids?

(3) Cardio-Pulmo-Renal Rehabilitation (34 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions